Palisade Bio Announced The Receipt Of The Second Milestone Payment To Giiant From The U.S. Crohn's And Colitis Foundation

Palisade Bio, Inc. - Common Stock -7.10%

Palisade Bio, Inc. - Common Stock

PALI

4.71

-7.10%

- Company's co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding as part of previously announced grant from the US Crohn's and Colitis Foundation

- Lead program, PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via